NEW YORK, Feb. 6, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on ONCE, SYN, TGTX, and ZSAN which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, February 05, 2018, the NASDAQ Composite ended the trading session
Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock finished Monday's session 1.86% lower at $54.83 with a total trading volume of 510,552 shares. The Company's shares have advanced 5.77% in the last month. The stock is trading below its 50-day moving average by 4.54%. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have a Relative Strength Index (RSI) of 44.61.
On January 18th, 2018, research firm Credit Suisse initiated an 'Outperform' rating on the Company's stock, with a target price of $61 per share. Get the full research report on ONCE for free by clicking below at:
On Monday, shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 908,542 shares, which was above its three months average volume of 797.17 thousand shares. The stock ended the session 2.34% lower at $0.43. The stock is trading below its 50-day moving average by 21.98%. Moreover, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the US, have an RSI of 28.65. Get access to our top-rated research, including the free report on SYN at:
New York headquartered TG Therapeutics Inc.'s shares closed the day 1.69% higher at $12.00. The stock recorded a trading volume of 4.63 million shares, which was above its three months average volume of 1.35 million shares. The Company's shares have gained 35.59% in the last month, 49.07% over the previous three months, and 142.42% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 32.01% and 15.26%, respectively. Additionally, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 67.23. Click here to subscribe for a free membership which welcomes you with our report on TGTX at:
Shares in Fremont, California headquartered Zosano Pharma Corp. finished 10.69% lower at $5.18. The stock recorded a trading volume of 73,853 shares, which was above its three months average volume of 44.60 million shares. The stock is trading below its 50-day moving average by 52.84%. Furthermore, shares of Zosano Pharma, which develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients, have an RSI of 23.14. Join our big investor community at Wall St. Equities today and get your free report on ZSAN at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----spark-therapeutics-synthetic-biologics-tg-therapeutics-and-zosano-pharma-300593992.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All